Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

386
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
386
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

275
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
275
Cirrhosis I: Introduction01:23

Cirrhosis I: Introduction

32
Cirrhosis is a chronic, irreversible liver disease characterized by the widespread replacement of healthy liver tissue with fibrotic scar tissue and the formation of regenerative nodules.Etiology of cirrhosisCirrhosis results from sustained liver injury that triggers progressive fibrosis and structural remodeling. The underlying causes are diverse, encompassing common and less frequent clinical conditions. Regardless of the origin, all causes lead to chronic inflammation, hepatocyte loss, and...
32
Cirrhosis II: Pathophysiology01:24

Cirrhosis II: Pathophysiology

53
Cirrhosis is a progressive chronic liver injury caused by prolonged inflammation, excessive fibrotic remodeling, and impaired regeneration. Over time, repeated hepatic insults disrupt the liver’s architecture and function, leading to reduced blood flow, impaired bile drainage, and diminished metabolic capacity.Pathophysiology of cirrhosisCirrhosis arises from three main responses to chronic liver damage: inflammation, immune activation, and hepatocyte death. These processes lead to...
53
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug01:14

Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug

360
In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
360
Cholesterol: Significance and Regulation01:29

Cholesterol: Significance and Regulation

2.1K
Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
Considering cholesterol and...
2.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Consensus statement on the application of artificial intelligence in osteoporosis screening and management: perspectives from the Asia-Pacific region.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2026
Same author

DXA-derived biofidelic finite element models for quantifying the efficacy of hip protectors.

JBMR plus·2026
Same author

Trends in Low Muscle Mass and Sarcopenia Prevalence in Korea Using Korea National Health and Nutrition Examination Survey (KNHANES) 2024 and 2008-2011: The KSBMR-KSOS KNHANES DXA Joint Task Force Report.

Journal of bone metabolism·2026
Same author

Trends in Osteoporosis Prevalence in Korea Using Korea National Health and Nutrition Examination Survey (KNHANES) 2024 and 2008-2011: The KSBMR KNHANES DXA Task Force Report.

Journal of bone metabolism·2026
Same author

X-linked hypophosphatemia in the presence of a <i>CLDN16</i> variant: implications for renal handling and disease severity.

JCEM case reports·2026
Same author

Current Knowledge on Atypical Parathyroid Tumors and Emerging Strategies for Risk Stratification.

Endocrinology and metabolism (Seoul, Korea)·2026

Related Experiment Video

Updated: May 7, 2026

Bile Duct Ligation in Mice: Induction of Inflammatory Liver Injury and Fibrosis by Obstructive Cholestasis
08:56

Bile Duct Ligation in Mice: Induction of Inflammatory Liver Injury and Fibrosis by Obstructive Cholestasis

Published on: February 10, 2015

56.6K

Effect of liver dysfunction on circulating sclerostin.

Yumie Rhee1, Won Jin Kim, Ki Jun Han

  • 1Brain Korea 21 Project for Medical Science, Department of Internal Medicine, Endocrine Research Institute, Yonsei University College of Medicine, Seoul, Korea.

Journal of Bone and Mineral Metabolism
|October 16, 2013
PubMed
Summary

Circulating sclerostin levels are significantly higher in patients with liver cirrhosis, especially advanced stages. This finding suggests a potential role for the liver in sclerostin metabolism and bone health regulation.

More Related Videos

Murine Precision-Cut Liver Slices as an Ex Vivo Model of Liver Biology
12:36

Murine Precision-Cut Liver Slices as an Ex Vivo Model of Liver Biology

Published on: March 14, 2020

16.3K
Measurement of Liver Stiffness Using Atomic Force Microscopy Coupled with Polarization Microscopy
10:10

Measurement of Liver Stiffness Using Atomic Force Microscopy Coupled with Polarization Microscopy

Published on: July 20, 2022

5.7K

Related Experiment Videos

Last Updated: May 7, 2026

Bile Duct Ligation in Mice: Induction of Inflammatory Liver Injury and Fibrosis by Obstructive Cholestasis
08:56

Bile Duct Ligation in Mice: Induction of Inflammatory Liver Injury and Fibrosis by Obstructive Cholestasis

Published on: February 10, 2015

56.6K
Murine Precision-Cut Liver Slices as an Ex Vivo Model of Liver Biology
12:36

Murine Precision-Cut Liver Slices as an Ex Vivo Model of Liver Biology

Published on: March 14, 2020

16.3K
Measurement of Liver Stiffness Using Atomic Force Microscopy Coupled with Polarization Microscopy
10:10

Measurement of Liver Stiffness Using Atomic Force Microscopy Coupled with Polarization Microscopy

Published on: July 20, 2022

5.7K

Area of Science:

  • Bone Biology
  • Hepatology
  • Endocrinology

Background:

  • Sclerostin, a Wnt inhibitor from osteocytes, impacts bone formation.
  • The effect of liver function on sclerostin levels is not well understood.

Purpose of the Study:

  • To investigate the relationship between circulating sclerostin levels and liver function in patients with cirrhosis.

Main Methods:

  • Cross-sectional study comparing 47 liver cirrhosis patients with 50 healthy controls.
  • Serum sclerostin measured by ELISA.
  • Statistical analysis including regression to identify independent factors.

Main Results:

  • Serum sclerostin was significantly higher in cirrhosis patients (50.8 ± 38.2 pmol/L) versus controls (35.1 ± 8.8 pmol/L).
  • Elevated sclerostin persisted after adjusting for confounders.
  • Advanced cirrhosis (Child-Pugh B/C) showed higher sclerostin than early cirrhosis (Child-Pugh A) or controls.
  • Gender, diabetes, albumin, and creatinine were independent factors for sclerostin levels.

Conclusions:

  • Circulating sclerostin is elevated in liver cirrhosis, particularly in advanced stages.
  • Sclerostin levels correlate with markers of liver dysfunction, suggesting a role for the liver in sclerostin metabolism.